You are here

Article Text

Article menu

Download PDFPDF

XML
Rare disease
CASE REPORT
Limited auricular relapsing polychondritis in a child treated successfully with infliximab
  1. Jubran Theeb Alqanatish,
  2. Basma Ali Alfarhan and
  3. Sara Mohammed Qubaiban
  1. Department of Paediatrics, King Abdulaziz Medical City and King Saud Bin Abdulaziz University for Health Sciences - Ministry of National Guard, Riyadh, Saudi Arabia
  1. Correspondence to Dr Jubran Theeb Alqanatish, qanatishj{at}ngha.med.sa

Abstract

Relapsing polychondritis (RP) is a rare progressive and destructive multisystem disorder characterised by recurrent inflammation of cartilaginous structures. It is a rare disease in paediatrics compared with adults. In children, the diagnosis is either delayed or overlooked due to low incidence. Auricular chondritis has been described in more than half of paediatric cases with RP. However, isolated auricular chondritis has not been reported as the only presentation of pediatric-onset RP. We described a lad who presented with isolated auricular chondritis, which is refractory to conventional treatment, including glucocorticoids and methotrexate as steroid-sparing agent. Remission of his disease’s relapses was sustained with infliximab. Limited auricular involvement as a presenting feature of RP in the absence of systemic association is very rare in children. We describe a case of successful use of infliximab on limited auricular chondritis disease.

  • ear, nose and throat/otolaryngology
  • pathology

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

https://doi.org/10.1136/bcr-2018-227043

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Contributors BAA and SMQ made significant contributions to data acquisition. JTA worked on data analysis and interpretation, drafted and revised the manuscript. All authors read and approved the final manuscript.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Patient consent for publication Obtained.